Ozmosi | 1ST-104 Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

1ST-104

Alternative Names: 1ST-104, 1ST104, 1ST 104
Clinical Status: Active
Latest Update: 2026-01-26
Latest Update Note: Clinical Trial Update

Product Description

(Sourced from: https://www.1stbio.com/rd-pipeline/)

Mechanisms of Action: LRRK2 Inhibitor, ABL1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: 1ST Biotherapeutics
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 0: Parkinson's Disease

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title

09/17/2026

News Article

 1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson's Disease Candidate ‘1ST-104’

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions